[Functional and biochemical characteristics of the vasodilator effects of nebivolol in patients with arterial hypertension].
OBJECTIVE
To examine nebivolol-induced changes in endothelial vasomotor function and blood concentrations of nitric oxide (NO) metabolites in patients with arterial hypertension (AH).


METHODS
The impact of 8-week nebivolol monotherapy on 24-hour blood pressure (BP) monitoring, ECG, autonomic heart regulation, changes in endothelium-dependent vasodilation (EDVD) and endothelium-independent vasodilation, on the plasma concentration of NO metabolites, and on the endothelial responsiveness index (ERI) were studied in 30 patients with stages I-II AH.


RESULTS
Nebivolol provides a sufficient 24-hour BP monitoring, reduced heart rate, the incidence of supraventricular arrhythmias, and left ventricular myocardial mass with the optimization of autonomic cardiac regulation. The agent recovers NO-ergic regulation of endothelial vasomotor function in patients with AH by normalizing the basal level of NO and EDVD. The study of plasma NO metabolites before and during reactive hyperemia test with ERI calculation substantially extends an idea of the mechanisms of EDVD and supplements the diagnostic potentialities of this method.


CONCLUSIONS
Dysfunction of the vascular endothelial NO-producing system occurs in patients with AH. In addition to its positive effect on 24-hour BP profile and myocardial morphofunctional parameters, nebivolol restores the NO-ergic regulation of endothelial vasomotor function in patients with AH, by potentiating NO expression, and modulates steady-state vasodilation.
Gel'tser
B I
BI
Kotel'niko v
V N
VN
Savchenko
S V
SV
D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001578:Benzopyrans / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D004730:Endothelium, Vascular / Q000187:drug effects; D004983:Ethanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D009569:Nitric Oxide / Q000097:blood; D013997:Time Factors; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*
D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D014665:Vasodilator Agents; D000068577:Nebivolol; D009569:Nitric Oxide